Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.38 |
| ▸ | CHRNG | P07510 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRND | Q07001 | 1/20 | 0.38 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21122049 | 0.82 | CYP2A6 (0.50) | GRM5CYP2A6HDAC8CHRNA3CHRNB4 | |
| SCHEMBL12026637 | 0.79 | CYP19A1 (0.40) | CHRNA3CHRNB4CHRNB2CHRNA4 | |
| SCHEMBL15996479 | 0.78 | APP (0.32) | GRM5CYP2A6 | |
| SCHEMBL9918873 | 0.77 | CYP2A6 (0.33) | GRM5CYP2A6HDAC8CHRNA3CHRNB4 | |
| SCHEMBL171179 | 0.77 | CYP2A6 (0.33) | GRM5CYP2A6HDAC8CHRNA3CHRNB4 | |
| SCHEMBL725480 | 0.77 | PRMT5 (0.34) | — | |
| SCHEMBL15345779 | 0.75 | CYP1A1 (0.33) | HDAC8 | |
| SCHEMBL9918235 | 0.75 | GRM5 (0.32) | GRM5CYP2A6HDAC8CHRNA3CHRNB4 | |
| SCHEMBL28361799 | 0.74 | PRMT5 (0.33) | — | |
| SCHEMBL31014462 | 0.72 | GRM5 (0.51) | GRM5CYP2A6HDAC8CHRNA3CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739096-B2 | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | PYRAMID BIOSCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210379033-A1 | METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-12-09 | — | — | US | disclosed |
| US-20190314407-A1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| US-20130165473-A1 | Azaquinolinone Derivatives and Uses Thereof | ASTRAZENECA AB (SE) | 2013-06-27 | — | — | US | disclosed |
| US-8466288-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-18 | — | — | US | disclosed |
| US-8343996-B2 | Azaquinolinone derivatives and uses thereof | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-20120202784-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120040950-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20100130540-A1 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | LINK MEDICINE CORPORATION (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739096-B2 | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | DTYMK, DCK, MAP3K9 | GRM5 1014/4885CYP2A6 3219/4885HDAC8 1126/4885 |
| US-20100130540-A1 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | TPMT, AZI2, NNMT | GRM5 458/4885CYP2A6 843/4885HDAC8 11/4885 |
| US-20120040950-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | GRM5 2008/4885CYP2A6 3314/4885HDAC8 444/4885 |
| US-20130165473-A1 | Azaquinolinone Derivatives and Uses Thereof | TPMT, AZI2, NNMT | GRM5 458/4885CYP2A6 843/4885HDAC8 11/4885 |
| US-20120202784-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | GRM5 2008/4885CYP2A6 3314/4885HDAC8 444/4885 |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | GRM5 1043/4885CYP2A6 3831/4885HDAC8 1199/4885 |
| US-20210379033-A1 | METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS | AHR, ARNT, NCOR1 | GRM5 621/4885CYP2A6 221/4885HDAC8 565/4885 |
| US-20190314407-A1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | AHR, HCLS1, IL2RA | GRM5 1877/4885CYP2A6 763/4885HDAC8 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.